Initiator Pharma (INIT) Q3 2024 earnings summary

Executive summary

• Focused on advancing pudafensine for erectile dysfunction (ED), expanding into pain and female sexual dysfunction (FSD), and strengthening patent protection.

• Published international patent application for pudafensine's dosage regime in ED, extending protection until 2044.

• Positive Phase IIb data for pudafensine in moderate-to-severe organic ED; strong support for further development.

• Business development efforts ongoing, with increased interest from regional and global partners in sexual health franchise.

Financial highlights

• No revenue generated in Q3 or the first nine months of 2024.

• Operating loss of KDKK 3,233 in Q3 2024 (improved from -5,191 in Q3 2023); nine-month operating loss KDKK 11,801 (improved from -22,750 in 2023).

• Net loss after tax for Q3 was KDKK 3,172 (Q3 2023: -4,614); nine-month net loss KDKK 12,081 (2023: -24,303).

• Cash and cash equivalents at September 30, 2024: KDKK 11,979 (down from KDKK 24,336 at year-end 2023).

• Equity at September 30, 2024: KDKK 15,744 (up from KDKK 11,162 at year-end 2023), reflecting conversion of MAC Clinical Research receivable.

Outlook and guidance

• Focus remains on advancing pudafensine for ED and FSD, with anticipation of greater efficacy in longer Phase III studies.

• Ongoing business development meetings and increased market attention expected to generate shareholder value.

• Continued emphasis on cost control and value creation.